Prosecution Insights
Last updated: November 04, 2026
Application No. 17/416,868

Extract of Chlamydomonas Acidophila, Method for Preparing Same and Cosmetic Compositions and Dermatological Compositions Comprising Same

Final Rejection §101§112
Filed
Nov 19, 2021
Priority
Dec 28, 2018 — FR 1874321 +1 more
Examiner
AFREMOVA, VERA
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Laboratoires Expanscience
OA Round
4 (Final)
51%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 51% of resolved cases
51%
Career Allowance Rate
449 granted / 888 resolved
-9.4% vs TC avg
Strong +29% interview lift
Without
With
+29.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
48 currently pending
Career history
959
Total Applications
across all art units

Statute-Specific Performance

§101
8.0%
-32.0% vs TC avg
§103
45.9%
+5.9% vs TC avg
§102
18.9%
-21.1% vs TC avg
§112
21.6%
-18.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 888 resolved cases

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of claims Claims 17-21, 23-30, 33-38 as amended and new claims 40 and 41 as filed on 7/28/2026 are currently pending. Claims 17-21, 23, 36-38 as amended and new claims 40 and 41 as filed on 7/28/2026 are under examination in the instant office action. Claims 24-30 and 33-35 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to nonelected invention(s), there being no allowable generic or linking claim. Applicant timely traversed the restriction requirement in the reply filed on 8/01/2024. In response to the office action, please, cancel non-elected, withdrawn and non-examined claims. Claim Rejections - 35 USC § 112 Claim 21 as amended is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 21 now recites a broader range for MW of the same peptides as in the claim 17, which is limited to MW less than 1000 DA. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c).The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claim 21 as amended is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 21 now recites a broader range for MW of the same peptides as in the claim 17, which is limited to MW less than 1000 DA. Thus, it fails to include all the limitations of the claim upon which it depends. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Response to Arguments Applicant's arguments filed on 7/28/2026 with respect to the clams as currently amended have been fully considered and are persuasive. The rejection of claims under 35 U.S.C. 102 (a) (1) as being anticipated by Gerloff-Elias et al (FEMS Microbiol Ecol, 2006, 56, pages 345-354) in the light of evidence by Borges et al (Front Immunol. 2012 May, Vol. 3, article 95, pages 1-2) has been withdrawn in view of claim amendment drawn to peptide weight of less than 1000kDa in amount 80% in the extract and applicants’ arguments that the cited reference discloses only heat-shock proteins (HSP). The HSP as described therein have MW 25kDA which is higher than recited in the amended claims (response pages 7-9). The rejection of claims under 35 U.S.C. 103 as being unpatentable over BR 102014023096 (Lisboa et al), Samarakoon et al (Food Research International, 2012, 48, pages 948-960) and Morris et al (Bioresource Technology, 2008, 99, pages 7723-7729) has been withdrawn in view of current amendment and applicants’ arguments that none of the cited prior art refence teach or suggest a beneficial antioxidant and anti-inflammatory peptide extract from a particular microalgal species of Chalmydomonas acidophila which is obtained by alkaline protease hydrolysis and characterized by specific 80% content of peptides having MW less than 1000 DA as recited by the amended claims (response pages 9-14). The rejection of claim under 35 U.S.C. 101 has been withdrawn in view of current amendment and applicants’ arguments that claimed extract is not a natural product because alkaline hydrolysis of Chalmydomonas acidophila modified peptide structure by increasing amount of small MW peptide molecules and increasing Chalmydomonas acidophila modified peptide bioavailability or biological activity (response pages14-15). Claims 17-21, 23, 36-38, 40 and 41 are free from prior art of record. Claims 17-20, 23, 36-38, 40 and 41 are allowed. In response to the office action, please, cancel non-elected, withdrawn and non-examined claims 24-30 and 33-35. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to VERA AFREMOVA whose telephone number is (571)272-0914. The examiner can normally be reached Monday-Friday: 8.30am-5pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sharmila Landau can be reached on (571) 272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Vera Afremova October 22, 2026 /VERA AFREMOVA/ Primary Examiner, Art Unit 1653
Read full office action

Prosecution Timeline

Show 3 earlier events
Mar 31, 2025
Final Rejection mailed — §101, §112
Jun 30, 2025
Request for Continued Examination
Jul 07, 2025
Response after Non-Final Action
Dec 11, 2025
Non-Final Rejection mailed — §101, §112
May 11, 2026
Response Filed
May 11, 2026
Response after Non-Final Action
Jul 28, 2026
Response Filed
Oct 26, 2026
Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779001
APPLICATION OF TRADITIONAL CHINESE MEDICINE COMPOSITION IN PREPARATION OF DRUGS FOR TREATING NEURITIS
2y 5m to grant Granted Nov 03, 2026
Patent 12766172
COMPOSITION FOR PREVENTING, TREATING, OR IMPROVING GASTROINTESTINAL DISEASES COMPRISING STRAIN OF GENUS CORYNEBACTERIUM AND CULTURE THEREOF
4y 10m to grant Granted Oct 20, 2026
Patent 12747444
Heterotrophic Production Methods for Microbial Biomass and Bioproducts
5y 6m to grant Granted Sep 29, 2026
Patent 12721871
PROBIOTICS FOR THE PREVENTION OR TREATMENT OF VIRAL RESPIRATORY INFECTIONS
1y 10m to grant Granted Sep 01, 2026
Patent 12708650
Recombinant Bacteria And Uses Thereof
4y 11m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
51%
Grant Probability
80%
With Interview (+29.4%)
3y 7m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 888 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month